AZD8421
Sponsors
Astrazeneca AB, AstraZeneca
Conditions
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Active, not recruitingNCT06188520
Start: 2023-12-05End: 2027-06-30Updated: 2026-10-28
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors (CYCAD-1)
RecruitingCTIS2023-507305-33-00
Start: 2024-04-29Target: 28Updated: 2026-01-22